Company intelligence / Profile preview

Adare Biome

Ownership: Public · DSM
Development stage: Other

Overview

Adare Biome has commercialized its lead pharmaceutical product Lactéol™, which has broad international distribution. Its postbiotic ingredients LBiome™ and LBiotix™ are used in human, pet, and production animal digestive health applications. The company’s acquisition by dsm-firmenich aims to expand its reach into new markets including dietary supplements and early life/medical nutrition. No clinical trial data was identified.

Therapeutic areas: GastroenterologyMetabolic Disorders
Modalities: Postbiotic therapyMicrobial therapy
Industry: Biotech

Partnerships

Now part of dsm-firmenich group partnerships

Beyond the preview

Go deeper on Adare Biome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adare Biome.